Clinical Trial Update: Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME) [Phase 3]

View source ↗

Summary

Phase 3 EXTREME trial evaluating cetuximab added to platinum-based chemotherapy and 5-fluorouracil as first-line therapy for recurrent/metastatic squamous cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• 5-Fluorouracil (5-FU)
• CARBOPLATIN (Carboplatin)
• CISPLATIN (cisplatin)
• ERBITUX (cetuximab)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Head and Neck Cancer | Phase 3 | Status: COMPLETED | Results posted: 2011-09-30